Pharmacokinetics, pharmacodynamics and pharmacogenetics study of eribulin mesylate in patients with unresectable advanced or recurrent breast cancer

Trial Profile

Pharmacokinetics, pharmacodynamics and pharmacogenetics study of eribulin mesylate in patients with unresectable advanced or recurrent breast cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 May 2016

At a glance

  • Drugs Eribulin (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 11 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top